The burden of bladder cancer in the United States is large and expanding with the aging population; the annual incidence has increased from approximately 50 000 cases per year in the 1990s1 to nearly 80 000 new cases projected for 2017.2 Non–muscle-invasive bladder cancers represent approximately 75% of all incident cases,3 of which the majority are low-grade tumors. Low-grade bladder cancers frequently recur but rarely result in cancer progression or death. In addition to being the most expensive cancer per patient,4 bladder cancer disproportionately affects older patients, with a median age at diagnosis of 73 years, the oldest age at diagnosis of all cancer sites.5 Thus, patients with low-grade bladder cancer often live with this diagnosis as one of multiple chronic conditions.6
Kaffenberger SD, Miller DC, Nielsen ME. Simplifying Treatment and Reducing Recurrence for Patients With Early-Stage Bladder Cancer. JAMA. 2018;319(18):1864–1865. doi:10.1001/jama.2018.4656
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: